Literature DB >> 2526870

Experimental infection of cynomolgus monkeys (Macaca fascicularis) with HIV-2.

P Putkonen1, B Böttiger, K Warstedt, R Thorstensson, J Albert, G Biberfeld.   

Abstract

Ten healthy adult cynomolgus monkeys (Macaca fascicularis) were inoculated with two different isolates of human immunodeficiency virus type 2 (HIV-2), SBL-6669 and SBL-K135, to establish an animal model for HIV infection. HIV-2SBL-6669 had been propagated for a long time in continuous human cell lines whereas HIV-2SBL-K135 had been grown only in fresh human and monkey lymphocyte cultures or previously for a short time in a continuous cell line. Virus was isolated from three or four animals inoculated with HIV-2SBL-K135 but in none of six monkeys inoculated with HIV-2SBL-6669. All animals seroconverted although the antibody response was higher in SBL-K135 virus-infected monkeys. Varying degrees of lymphadenopathy were observed but there were no significant changes in the numbers of CD4+ and CD8+ T cells. The infection was transferred to two monkeys inoculated with blood from a previously SBL-K135 virus-infected monkey. Four animals inoculated with HIV-2SBL-K135, which had never been propagated in continuous human cell lines, showed strong antibody responses against both gag- and env- encoded proteins of HIV-2. None of the SBL-6669 infected monkeys showed antibodies to core proteins. HIV-2 infection of cynomolgus monkeys represents a useful experimental model for HIV vaccine trials and antiviral testing.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2526870

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  17 in total

1.  A specific region of 37 amino acid residues in the SPRY (B30.2) domain of African green monkey TRIM5alpha determines species-specific restriction of simian immunodeficiency virus SIVmac infection.

Authors:  Emi E Nakayama; Hiroyuki Miyoshi; Yoshiyuki Nagai; Tatsuo Shioda
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

2.  Persistent infection of rhesus macaques with a molecular clone of human immunodeficiency virus type 2: evidence of minimal genetic drift and low pathogenetic effects.

Authors:  G Franchini; P Markham; E Gard; K Fargnoli; S Keubaruwa; L Jagodzinski; M Robert-Guroff; P Lusso; G Ford; F Wong-Staal
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

3.  Tackling HIV and AIDS: contributions by non-human primate models.

Authors:  Koen K A Van Rompay
Journal:  Lab Anim (NY)       Date:  2017-05-22       Impact factor: 12.625

4.  Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity.

Authors:  E Björling; K Broliden; D Bernardi; G Utter; R Thorstensson; F Chiodi; E Norrby
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

5.  Genetic variation in a human immunodeficiency virus type 2 live-virus Macaca nemestrina vaccine model.

Authors:  A Radaelli; G Kraus; A Schmidt; P Badel; J McClure; S L Hu; W Morton; C De Giuli Morghen; F Wong-Staal; D Looney
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

Review 6.  Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Authors:  E Sandström; B Oberg
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

7.  Generation, characterization and cross-reactivities of monoclonal antibodies against the p24 core protein and the gp130 envelope glycoprotein of HIV-2ben.

Authors:  A C Faisst; A Otteken; S Nick; G Hunsmann
Journal:  Med Microbiol Immunol       Date:  1993-07       Impact factor: 3.402

8.  Evolution of the human immunodeficiency virus type 2 envelope gene in preimmunized and persistently infected rhesus macaques.

Authors:  M H Bäyon-Auboyer; F D Boussin; G Vogt; R Le Grand; B Vaslin; I Nicol-Jourdain; D Dormont
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

9.  Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates.

Authors:  M Robert-Guroff; K Aldrich; R Muldoon; T L Stern; G P Bansal; T J Matthews; P D Markham; R C Gallo; G Franchini
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

10.  Penetration of zidovudine and 3'-fluoro-3'-deoxythymidine into the brain, muscle tissue, and veins in cynomolgus monkeys: relation to antiviral action.

Authors:  E Ljungdahl-Ståhle; E Guzenda; D Böttiger; B Wahren; B Oberg; L Ståhle
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.